Daptomycin use in patients with cancer and neutropenia: Data from a retrospective registry

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 4, 2010, Pages 249-257

  Rolston, Kenneth V I ^a   McConnell, Scott A ^b   Brown, Jack ^c   Lamp, Kenneth C ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cancer; Daptomycin; Enterococci; Neutropenia

Indexed keywords

CEFEPIME; DAPTOMYCIN; IMIPENEM; LINEZOLID; MEROPENEM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACKACHE; BACTEREMIA; CANCER PATIENT; CARDIOPULMONARY INSUFFICIENCY; CATHETER INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONGESTIVE HEART FAILURE; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NAUSEA; NEUTROPENIA; OSTEOMYELITIS; PYELONEPHRITIS; REGISTER; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77954081274     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bodey GP. Infection in cancer patients. A continuing association. Am J Med. 1986;81:11-26.
2. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
3. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51-S59.
4. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103-1110.
5. Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis. 2003;37:1144-1145.
6. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490-494.
7. Rolston KV, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. Int J Infect Dis. 2006;10:223-230.
8. Diekema DJ, Coffman SL, Marshall SA, Beach ML, Rolston KV, Jones RN. Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers. Antimicrob Agents Chemother. 1999;43:940-943.
9. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34: 730-751.
10. Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40(Suppl 4):S246-S252.
11. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(Suppl 1):S3-S4.
12. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Grampositive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988;108:30-35.
13. Cometta A, Kern WV, de Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillintazobactam monotherapy. Clin Infect Dis. 2003;37:382-389.
14. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis. 1999;29: 503-507.
15. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995;20:1126-1133.
16. Safdar A, Rolston KV. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer. 2006;106:1815-1820.
17. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398-2402.
18. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillinresistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004;38:1700-1705.
19. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193-200.
20. Finberg RW, Moellering RC, Tally FP, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis. 2004;39:1314-1320.
21. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44:1208-1215.
22. Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother. 2006;18:27-32.
23. Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillinsusceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother. 2007;51:1787-1794.
24. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005;55:283-288.
25. Kapadia M, Coyle E, Prince R, Rolston K. Declining in vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. Presented at: 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16-19, 2005; Washington, DC. Abst E-807.
26. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-1681.
27. Fowler VG Jr, Boucher HW, Corey R, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
28. Barber GR, Lauretta J, Saez R. A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin. Pharmacotherapy. 2007;27:927-932.
29. Mergenhagen KA, Pasko MT. Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis. Ann Pharmacother. 2007;41:1531-1535.
30. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007;54:567-571.
31. Hogan HL, Adachi JA, Coyle EA, Rolston KVI. Daptomycin therapy of gram-positive infections (GPI) in pediatric cancer patients. Presented at: 14th International Symposia on Infections in the Immunocompromised Host; June 2007; Thessaloniki, Greece.
32. Hogan H, Raad I, Rolston K. Daptomycin therapy for gram-positive infections in cancer patients. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 25th International Congress of Chemotherapy; March 31-April 3, 2007; Munich, Germany. Abstract P-1666.
33. Rolston KV, Segreti J, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007;120:S4-S5.
34. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis. 1992;15(Suppl 1):S206-S215.
35. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1995;39:445-452.
36. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycinresistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis. 1996;23:1234-1239.
37. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis. 2008;46:30-36.
38. Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53:428-434.
39. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597-607.
40. Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control. 2006;34:534-536.
41. Rhee KY, Gardiner DF, Charles M. Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin Infect Dis. 2005;40:1705-1706.
42. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883-3886.
43. Rolston KV. Review: Daptomycin for the treatment of gram-positive infections in neutropenic cancer patients. Clin Adv Hematol Oncol. 2008;6:815-817.
44. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007;51:1656-1660.
45. ZYVOX® (linezolid) [package insert]. New York, NY: Pharmacia & Upjohn: Division of Pfizer, Inc; 2008.
46. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8:53-66.
47. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27:1189-1197.
48. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.
49. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149-2152.
50. Rolston KVI, Bodey GP. Infections in patients with cancer. In: Kufe DW, Frei EI, Holland JF, et al, eds. Cancer Medicine. 7th ed. Hamilton, Ontario, Canada: BC Decker, Inc., 2006:2222-2245.